636-95-3

Basic information

• Product Name: 3-Nitrophenylhydrazine hydrochloride
• Synonyms: 3-Nitrophenylhydrazine Hydrochloride, 97+%;3-NITROPHENYLHYDRAZINE HYDROCHLORIDE;M-NITROPHENYLHYDRAZINE HCL;M-NITROPHENYLHYDRAZINE HYDROCHLORIDE;3-nitrophenylhydrazinium(1+) chloride;3-NITROPHENYLHYDRAZINE HYDROCHLORIDE, 98 %;3-NitrophenylhydrazineHcl;3-NITROPHENYLHYDRAZINE HYDROCHLORIDE 98%
• CAS NO: 636-95-3
• Molecular Formula: C₆H₈N₃O₂*Cl
• Molecular Weight: 189.6
• EINECS: 211-270-6
• Product Categories: Hydrazines;Nitrogen Compounds;Organic Building Blocks
• Mol File: 636-95-3.mol
• Article Data: 6

Chemical Properties

• Melting Point: 210 °C (dec.)(lit.)
• Boiling Point: 317.5 °C at 760 mmHg
• Flash Point: 145.8 °C
• Appearance: yellow crystalline powder
• Density: 1.419 g/cm³
• Vapor Pressure: 0.000384mmHg at 25°C
• Storage Temp.: Flammables area
• Solubility: DMSO, Methanol (Slightly)
• BRN: 3569013
• CAS DataBase Reference: 3-Nitrophenylhydrazine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Nitrophenylhydrazine hydrochloride(636-95-3)
• EPA Substance Registry System: 3-Nitrophenylhydrazine hydrochloride(636-95-3)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 26-37/39-36
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 636-95-3(Hazardous Substances Data)

Usage

Chemical Properties

YELLOW CRYSTALLINE POWDER

Uses

3-Nitrophenylhydrazine Hydrochloride acts as a reagent in the preparation of isosteviol-fused pyrazolines and pyrazoles as potential anticancer agents, preparation of pyrazolobenzothiazines as inhibitors of hepatitis C virus replication.

InChI:InChI=1/C6H7N3O2.ClH/c7-8-5-2-1-3-6(4-5)9(10)11;/h1-4,8H,7H2;1H

Upstream product

• 99-09-2 3-nitro-aniline 

Downstream Products

• 128102-57-8 phenyl-(5-phenyl-[1,2,4]oxadiazol-3-yl)-methanone (3-nitro-phenyl)-hydrazone 
• 80815-93-6 3-benzoyl-5-phenyl-1,2,4-oxadiazole m-nitrophenylhydrazone 
• 113752-93-5 N-(3-nitro-phenyl)-N'-trityl-hydrazine 
• 79984-67-1 N-(m-Nitrophenyl)-N'-propionylhydrazine 
• 476637-05-5 2-(3-nitrophenyl)-5-tert-butyl-2H-pyrazol-3-yl-amine 
• 672305-19-0 Z-6-trimethylsianyl-hexa-3,5-diyn-2-one 3-nitrophenylhydrazone 
• 346440-86-6 3,5-dimethyl-1-(3-nitrophenyl)-1H-pyrazole-4-carboxylic acid ethyl ester 
• 904679-44-3 N-(4,4'-dihydroxybenzhydrylidene)-N'-(3-nitrophenyl)hydrazine 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.